Drugs / TAK-379
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00722917 | Jul 2008 → Apr 2009 | type 2 diabetes mellitus | Takeda | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAK-379 | “Takeda Pharmaceutical Company Limited is developing TAK-379, a non-thiazolidinedione partial proliferator-activated receptor agonist for the treatment of type 2 diabetes mellitus.” NCT00722917 ↗ |
| Action | Activate | “partial proliferator-activated receptor agonist” NCT00722917 ↗ |
| Route | Oral | “TAK-379 25 mg, tablets, orally, once daily” NCT00722917 ↗ |